Showing results (241-250 of 254) with videos related to
Sort By:
Pageof 26
Molecular and Cellular Probes|April 26, 2011
Specific detection of Angiostrongylus cantonensis in the snail Achatina fulica using a loop-mediated isothermal amplification (LAMP) assayChun-Yan Liu, Hui-Qun Song, Ren-Li Zhang, et al.Clinical and Vaccine Immunology : CVI|November 26, 2010
Protective immunity induced by Toxoplasma gondii rhoptry protein 16 against toxoplasmosis in miceZi-Guo Yuan, Xiu-Xiang Zhang, Xian-Hui He, et al.Transboundary and Emerging Diseases|April 30, 2025
The Genetic Diversity and Interspecific Transmission of Circovirus in Rhizomys sinensis in Guangdong, Southern ChinaZhaowen Ren, Zi-Guo Yuan, Shengjun Luo, et al.International Medical Case Reports Journal|May 22, 2024
Successful Treatment of Severe Case of Lipid Overload Syndrome with Pancreatitis and Pneumonia: A Case ReportZi-Guo Sun, Shi-Cheng Xu, Qin Yang, et al.International Journal of Biological Sciences|January 29, 2026
Targeting CDC42 Protects Mitochondrial Function through KLF2/HIF-1α/PINK1 Signaling in Acute Kidney InjuryXue Zhou, Xian Fu, Yi-Wen Meng, et al.Journal of Cancer|May 6, 2020
Adjuvant transarterial chemoembolization following radical resection for intrahepatic cholangiocarcinoma: A multi-center retrospective studyLei Wang, Zi-Guo Lin, Qiao Ke, et al.Plant, Cell & Environment|May 12, 2026
miR164c-CUC2 Module Modulates Salinity Stress Tolerance in Soybean by Regulating Abscisic Acid Signalling and Reactive Oxygen Species Scavenging PathwaysShi-Jia Wang, Tai-Fei Yu, Shu-Yu Wu, et al.Diabetologia|March 9, 2021
Efficacy and safety of PEGylated exenatide injection (PB-119) in treatment-naive type 2 diabetes mellitus patients: a Phase II randomised, double-blind, parallel, placebo-controlled studyLinong Ji, Ying Du, Min Xu, et al.Journal of Medical Virology|July 7, 2021
Emergence of a young case infected with avian influenza A (H5N6) in Anhui Province, East China during the COVID-19 pandemicJun-Ling Yu, Sai Hou, Ya-Ting Feng, et al.Annals of the Rheumatic Diseases|February 7, 2025
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trialJinjing Liu, Ying Jiang, Shangzhu Zhang, et al.Pageof 26